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Abstract
Background and objective
Early detection methods for pancreatic cancer are lacking. We aimed to develop a prediction
model for pancreatic cancer based on changes in health captured by healthcare claims
data.
Methods
We conducted a case-control study on 29,646 Medicare-enrolled patients aged 68 years
and above with pancreatic ductal adenocarcinoma (PDAC) reported to the Surveillance Epi-
demiology an End Results (SEER) tumor registries program in 2004–2011 and 88,938 age
and sex-matched controls. We developed a prediction model using multivariable logistic
regression on Medicare claims for 16 risk factors and pre-diagnostic symptoms of PDAC
present within 15 months prior to PDAC diagnosis. Claims within 3 months of PDAC diagno-
sis were excluded in sensitivity analyses. We evaluated the discriminatory power of the
model with the area under the receiver operating curve (AUC) and performed cross-valida-
tion by bootstrapping.
Results
The prediction model on all cases and controls reached AUC of 0.68. Excluding the final 3
months of claims lowered the AUC to 0.58. Among new-onset diabetes patients, the predic-
tion model reached AUC of 0.73, which decreased to 0.63 when claims from the final 3
months were excluded. Performance measures of the prediction models was confirmed by
internal validation using the bootstrap method.
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Conclusion
Models based on healthcare claims for clinical risk factors, symptoms and signs of pancre-
atic cancer are limited in classifying those who go on to diagnosis of pancreatic cancer and
those who do not, especially when excluding claims that immediately precede the diagnosis
of PDAC.
Introduction
Over 50,000 new cases and 40,000 deaths from pancreatic cancer occur annually in the U.S.[1]
With a 5-year survival proportion below 10%, pancreatic cancer is the deadliest solid organ
cancer. [1, 2] If current trends continue, pancreatic cancer will become the second leading
cause of cancer death by 2030. [3] Most pancreatic cancer patients have advanced stage disease
at diagnosis; [1] therefore, strategies for detecting pancreatic cancer earlier could expand treat-
ment options and improve survival.
Metabolic and gastrointestinal changes are strongly associated with incident pancreatic
cancer. For example, people with new diagnoses of diabetes are at�4 -fold increased risk of
pancreatic cancer diagnosis in the next two years. [4–6] In some patients, new-onset diabetes
reflects a paraneoplastic phenomenon arising from tumor in the pancreas. [7, 8] Development
of pancreatic ductal adenocarcinoma (PDAC) is also often marked with unintentional weight
loss. [9] Recent diagnosis of pancreatitis is also strongly associated with PDAC risk with an
odds ratio (OR) of 13.6, reflecting potential misdiagnosis of PDAC as pancreatitis, or the cau-
sation of pancreatitis by the developing neoplasm. [10] Similarly, recent initiation of proton-
pump inhibitor (PPI) use is related to PDAC risk (OR = 6.2), suggesting that PDAC-related
abdominal discomfort is sometimes treated as dyspepsia. [11]
Collectively, changes in health as manifested in healthcare claims could potentially be used
to detect PDAC at earlier stages. Previous prediction models for PDAC that have incorporated
data on changes in health have shown modest discriminative power, but have varied applica-
bility to the general population in the U.S. [11–13] We hypothesize that predictive modeling
using healthcare claims from a national insurance program in the U.S. can help identify older
adults who are at high risk of pancreatic cancer. Using Medicare-linked data on cancer diagno-
ses reported to Surveillance, Epidemiology, and End Results (SEER) cancer registries between
January 2004 and December 2011, we conducted a matched retrospective case-control study
to develop a prediction model for pancreatic cancer.
Materials and methods
Data sources
The SEER database includes information on cancer incidence and survival from population-
based registries in geographic regions currently comprising approximately 28% of the U.S.
population. [14] Linkage of SEER to Medicare claims on inpatient and outpatient procedures
and diagnoses offers unique population-based source of information on patterns of care before
and after diagnosis that can be used for epidemiological and health services research. [15, 16]
For the purposes of the current analyses, we extracted pathology and diagnosis information on
PDAC cases from SEER, selected controls from a matched random sample of Medicare mem-
bers, and extracted covariate data from Medicare claims. SEER-Medicare data pertaining to
pancreatic cancer cases and controls were obtained and analyzed as a limited data set without
Healthcare claims and diagnosis of pancreatic cancer
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direct identifiers. The Institutional Review Board of Cedars-Sinai Medical Center has
approved this study.
Selection of cases
Based on topography code C25.x and ICD-O-3 histology codes for adenocarcinoma of the
pancreas (8000, 8010, 8020, 8021, 8022, 8050, 8140, 8141, 8211, 8230, 8260, 8441, 8450, 8453,
8470, 8471, 8472, 8473, 8480, 8481, 8500, 8503, 8521), [17] we identified all newly diagnosed
PDAC patients at least 68 years old. We chose 68 years as the minimum age so that eligible
patients had at least three years enrollment duration in Medicare Parts A and B prior to diag-
nosis of pancreatic cancer. We only included people with PDAC that was confirmed by
microscopy, laboratory test, direct visualization, or imaging, and excluded cases with unknown
months of diagnoses or those diagnosed at autopsy. Because SEER reports only the month and
year of cancer diagnosis, we set the 1st of the month as the diagnosis date for the purposes of
designating pre-diagnosis claims.
Selection of controls
Using the 5% random sample of Medicare beneficiaries, we selected 3 controls for each case
and matched them by sex, 5-year age group and year of diagnosis. Controls were free of pan-
creatic cancer as of July 1st of the same year as case diagnosis, and had been enrolled in Medi-
care A and B for at least three years as of that point in time. This methodology parallels control
selection methods by Engels, et al. [18] The same control was allowed to be sampled across
multiple years; however each control was only sampled once in a calendar year. Index date was
defined as July 1st of the same year as the matched case.
Covariates
On the basis of consensus between investigators with expertise in oncology, gastroenterology
and epidemiology and published literature, we selected clinical health changes known to be
associated with PDAC, including acute pancreatitis, chronic pancreatitis, any abdominal pain,
chest pain, diabetes mellitus, weight loss/anorexia/cachexia, nausea and/or vomiting, digestive
problems, dyspepsia/gastritis/peptic ulcer disease, fatigue, itching/pruritis, depression, jaun-
dice, gallbladder disease, acute cholecystitis, and esophageal reflux. S1 Table lists these covari-
ates and their corresponding ICD-9 codes. We extracted ICD-9 coded claims for these factors
from Medicare inpatient and outpatient data files.
Healthcare access
Healthcare claims are more likely to be consistent among patients who make use of recom-
mended preventive services. A proxy indicator for such individuals among Medicare enrollees
is compliance with the annual influenza vaccine recommendation, which is correlated with
health literacy and motivation to seek care. [19, 20] To adjust for healthcare access, we
included influenza vaccination in all models. Compliance with the vaccine recommendation
was determined by extracting claims data on receipt of influenza vaccination (HCPCS codes
G0008, Q2035, Q2036, Q2037, Q2038) in the 12-month period prior to index date.
Statistical analysis plan
To visualize the trends of claims for covariates of interest prior to diagnosis with PDAC and to
identify a pre-diagnosis window of time when such trends diverge between cases and controls,
we summarized the ratios of percent of cases to controls who had healthcare claims for the
Healthcare claims and diagnosis of pancreatic cancer
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covariates of interest within 24 months prior to diagnosis. The 24-month history was divided
into 3-month intervals (total of 8 quarter years). For the purpose of the main prediction
model, we included claims within 15 months prior to PDAC diagnosis or index date to incor-
porate as many covariates that diverge between the cases and the controls, as well as to have
sufficient lead time prior to pancreatic cancer diagnosis to identify potentially useful early
detection signals.
To describe covariate distributions of the case and control sample groups, we computed fre-
quencies and percentages for categorical variables and medians and interquartile ranges for
continuous variables. The primary outcome was the occurrence of PDAC. We compared
covariate distributions between the case and control groups by Wilcoxon rank-sum statistics
or chi-square statistics, as appropriate. To quantify associations between the covariates and the
outcome, we constructed unconditional logistic regression models under adjustment for the
matching variables: sex, age group, and year of diagnosis. Because we sampled some patients
more than once, we accounted for repeated measurements on the same control across multiple
years by robust variance estimates. Variables initially considered for inclusion in the multivari-
able model included race and influenza vaccine status and all of the covariates described
above.
Model selection was conducted by stepwise variable selection procedure based on Quasi-
likelihood under the Independence model Criterion (QIC) statistic. [21, 22] The final multi-
variable model was chosen by the lowest QIC value, a statistical alternative to Akaike’s infor-
mation criterion [23] but for correlated data. Age group, sex, year of diagnosis, race and
influenza vaccine status were kept in the model regardless of statistical significance.
Model performance
We evaluated the sensitivity of the models at specificities of 99% or higher, 95–99%, and
<95%. We set thresholds based on specificity, rather than sensitivity, given the infrequency of
the disease, and the high cost of false positivity (e.g., patient anxiety, costly imaging). Perfor-
mance of the models on predicting occurrence of pancreatic cancer was further assessed with
measures of discrimination and calibration. [24] Discrimination was evaluated by receiver
operating characteristic (ROC) curve and area under the ROC curve (AUC, or C-index).16 Cal-
ibration of the prediction models was evaluated with calibration slope intercepts, and graphi-
cally assessed with predicted versus observed probability of the occurrence of PDAC based on
the loess algorithm. [25] Internal validation of the models was performed by estimating and
correcting for possible overfitting and optimism in the model performance estimates by boot-
strap methods with 1000 replicates. [25–27]
Sensitivity analyses
To evaluate how the prediction model may have been influenced by claims immediately pre-
ceding the diagnosis of PDAC, which may reflect diagnostic work-up for cancer, we conducted
sensitivity analyses excluding claims occurring less than 3 months prior to PDAC diagnosis.
Because new-onset diabetes can be an early indicator of pancreatic cancer, [7, 8] and has been
the focus of published prediction models, [11–13] we also performed sensitivity analyses
among those with new claims for diabetes within 15 months prior to the index date, without
any claim for diabetes prior to this period. Finally, a separate prediction model was also created
based on claims presented 16–24 months prior to the index date, to evaluate possible predic-
tion utility further before diagnosis. To consider the influence of including weak associations
in the prediction models, we also constructed models with parsimonious selection of variables
that were associated with PDAC with OR> 2 for each of the models above. In all models,
Healthcare claims and diagnosis of pancreatic cancer
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except for new-onset diabetes, we included relevant claims within the specified time period
whether or not they were the first ever claim for the condition.
All statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, North Caro-
lina) and R package version 3.5.0 (The R Foundation for Statistical Computing). The Institu-
tional Review Board of Cedars-Sinai Medical Center approved the study. We followed the
STROBE guidelines for reporting of results of case-control studies, [28] and the PROBAST
guidelines for reporting on potential bias and applicability of prediction models. [29]
Results
In total, 51,540 non-deceased pancreatic cancer patients with known diagnosis month and
year were reported to SEER between 2004 and 2011; 44,882 of these were malignant primary
PDAC. Diagnosis was confirmed by microscope or laboratory tests or by imaging in 41,305
cases, of whom 29,646 met all our study eligibility criteria. Of note, 23,332 of the cases were
microscopically confirmed (79%). We selected 88,938 controls matched to the cases. Table 1
provides characteristics of the cases and controls.
Pre-diagnostic claims history in cases and controls
Fig 1 illustrates the relative proportion of claims for each indicator in PDAC cases vs. control
within 24 months prior to the index date. Covariates such as chronic pancreatitis, acute pan-
creatitis, jaundice and poorly controlled diabetes are present in greater frequency in cases vs.
control from as early as 24 months prior to cancer diagnosis or matched date. In addition to
these factors, covariates such as upper abdominal pain, gallbladder disease, digestive symptoms
and weight loss were present in greater proportion of patients with pancreatic cancer than in
controls within 15 months prior to cancer diagnosis or matched date. All factors were more
elevated in cases vs. controls in the last 3 months prior to cancer diagnosis, and ratios for cases
vs. controls steeply increased in this quarter. (Fig 1) A summary of proportions of cases and
controls with claims for each covariate by quarter is provided in S2 Table.
Multivariable results
Table 2 shows the results of multivariable analyses. In the analyses focusing on the 15 months
before diagnosis, factors significantly associated with PDAC included black race (OR = 1.14)
relative to white race, and presence of at least 1 claim for acute pancreatitis, (OR = 4.72),
chronic pancreatitis (OR = 3.72), diabetes mellitus (OR = 1.52), dyspepsia (OR = 1.25), gall-
bladder disease (OR = 1.34), any abdominal pain (OR = 2.38), weight loss (OR = 2.70), and
jaundice (OR = 24.0). Influenza vaccination (OR = 0.82), depression (OR = 0.72), and chest
pain (OR = 0.89) were significantly associated with reduced PDAC risk.
Excluding claims from the final 3 months before index date weakened these associations.
For example, acute pancreatitis and jaundice were associated with 3.1-fold and 3.8-fold
increased risk of PDAC. The strength of the association for diabetes did not change with the
exclusion of the final 3 months of claims, but that for weight loss decreased from OR of 2.70 to
1.57. Dyspepsia and gallbladder disease were associated in the 1–15 month model were no lon-
ger significantly associated with PDAC risk when we excluded claims from the final 3 months.
Table 3 presents the covariate distributions between the case and control groups among
those with new-onset diabetes, comprising 7.8% of the cases (n = 2,319), and 3.8% of the con-
trols (n = 3,400). The results of the multivariable model for persons with new-onset diabetes
are presented in Table 4 and show similar trends to the entire case-control sample. Patients
with acute pancreatitis, chronic pancreatitis, abdominal pain, weight loss, and jaundice experi-
enced increased risk of PDAC. Also of note, in persons with new claims for diabetes, poorly
Healthcare claims and diagnosis of pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0218580 June 25, 2019 5 / 16
Table 1. Patient characteristics and presence of healthcare claims for covariates prior to pancreatic ductal adenocarcinoma diagnosis. Data are presented as number
of patients (%).
Variable Pancreatic cancer (N = 29646) Pancreatic cancer-Free (N = 88938) P-value
Sex
Male 12719 (42.9) 38157 (42.9) 1.000
Female 16927 (57.1) 50781 (57.1)
Age at diagnosis (Years)
68–70 3648 (12.3) 10789 (12.1) 0.003
71–75 7108 (24.0) 20880 (23.5)
76–80 7519 (25.4) 22457 (25.3)
81–85 6289 (21.2) 18674 (21.0)
86+ 5082 (17.1) 16138 (18.2)
Race
Black 2974 (10.0) 6813 (7.7) < .001
Other 2592 (8.7) 8402 (9.5)
White 24080 (81.2) 73723 (82.9)
Influenza vaccination in the last 12 months
Yes 11201 (37.78) 32637 (36.7) < .001
Presence of healthcare claims for clinical diagnoses
Acute pancreatitis
� 15 months of index date 2045 (6.90) 483 (0.54) < .001
Excluding final 3 months 721 (2.43) 389 (0.44) < .001
Chronic pancreatitis
� 15 months of index date 807 (2.72) 135 (0.15) < .001
Excluding final 3 months 344 (1.16) 112 (0.13) < .001
Diabetes mellitus
� 15 months of index date 10611 (35.8) 20414 (23.0) < .001
Excluding final 3 months 9320 (31.4) 19034 (21.4) < .001
Dyspepsia, gastritis, peptic ulcer disease
� 15 months of index date 1697 (5.72) 2373 (2.67) < .001
Excluding final 3 months 881 (2.97) 1960 (2.20) < .001
Gallbladder disease
� 15 months of index date 249 (0.84) 137 (0.15) < .001
Excluding final 3 months 83 (0.28) 115 (0.13) < .001
Acute cholecystitis
� 15 months of index date 286 (0.96) 218 (0.25) < .001
Excluding final 3 months 122 (0.41) 176 (0.20) < .001
Depression
� 15 months of index date 2493 (8.41) 7025 (7.90) 0.005
Excluding final 3 months 1918 (6.47) 6029 (6.78) 0.065
Presence of healthcare claims for symptoms and signs
Any abdominal pain
� 15 months of index date 11218 (37.8) 13423 (15.1) < .001
Excluding final 3 months 5389 (18.2) 11255 (12.7) < .001
Chest pain
� 15 months of index date 8359 (28.2) 18868 (21.2) < .001
Excluding final 3 months 6178 (20.8) 16044 (18.0) < .001
Gastrointestinal symptoms
� 15 months of index date 4302 (14.5) 7134 (8.02) < .001
(Continued)
Healthcare claims and diagnosis of pancreatic cancer
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controlled diabetes was additionally associated with PDAC risk. As in the model based on the
full subject sample, depression was negatively associated with PDAC risk. Excluding the final 3
months of claims eligibility attenuated the associations between the covariates and PDAC risk.
Regardless, acute pancreatitis, chronic pancreatitis, abdominal pain, weight loss, and jaundice
were associated with PDAC risk. Poorly controlled diabetes and nausea/vomiting were no lon-
ger associated with PDAC risk and omitted from the model, while depression and chest pain
were inversely associated with PDAC risk.
Model performance
Table 5 presents the performance measures of the multivariable regression models. The AUC
for the prediction model based on claims 1–15 months prior to PDAC, was 0.683. Excluding
claim from 3 months prior to index date reduced the AUC to 0.578. In contrast, excluding
non-microscopically confirmed cases increased the AUC slightly to 0.703. Optimism-cor-
rected AUCs confirmed the performance measures. We found good calibration between the
development and validation models with the optimism-corrected slope and intercept of 0.996
and -0.004, respectively, for the 1–15 months prediction model, and of 0.988 and -0.012 for the
model excluding 3 months of claims. At a specificity of 99%, the prediction model based on
�15 months claims yielded sensitivity of 16.2%, and the model excluding 3 months of claims
yielded sensitivity of 4.7%. A sensitivity of 16.2% translates to 1-year positive predictive value
of 1.2% if applied to a population aged�65 in whom the annual risk of PDAC is 70 cases per
100,000.[30] A sensitivity of 4.7% translates to 1-year positive predictive value of 0.33% if
applied to the same population.
The AUC and optimism-corrected AUC of the prediction model in persons with new-
onset diabetes reached 0.735 and 0.730 for all claims within 15 months of the index ate, 0.635
and 0.626 excluding claims from the final 3 months, and 0.754 and 0.747 excluding cases not
confirmed microscopically, respectively. Good calibrations remained for the prediction
Table 1. (Continued)
Variable Pancreatic cancer (N = 29646) Pancreatic cancer-Free (N = 88938) P-value
Excluding final 3 months 2420 (8.16) 5793 (6.51) < .001
Esophageal reflux
� 15 months of index date 5277 (17.8) 11245 (12.6) < .001
Excluding final 3 months 3551 (12.0) 9591 (10.8) < .001
Jaundice
� 15 months of index date 2531 (8.54) 196 (0.22) < .001
Excluding final 3 months 328 (1.11) 162 (0.18) < .001
Weight loss / Anorexia / Cachexia
� 15 months of index date 4956 (16.7) 4075 (4.58) < .001
Excluding final 3 months 1962 (6.62) 3263 (3.67) < .001
Nausea and/or vomiting
� 15 months of index date 3610 (12.2) 5378 (6.05) < .001
Excluding final 3 months 1820 (6.14) 4350 (4.89) < .001
Malaise/Fatigue
� 15 months of index date 46 (0.16) 89 (0.10) 0.015
Excluding final 3 months 35 (0.12) 87 (0.10) 0.347
Itching/pruritis
� 15 months of index date 678 (2.29) 1092 (1.23) < .001
Excluding final 3 months 356 (1.20) 896 (1.01) 0.005
https://doi.org/10.1371/journal.pone.0218580.t001
Healthcare claims and diagnosis of pancreatic cancer
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models in persons with new-onset diabetes. For these subjects, at a specificity of 99%, the pre-
diction model on�15 months claims yielded sensitivity of 18.2%, and excluding 3 months of
claims, 4.4%. The corresponding 1-year positive predictive values were 3.5% and 0.87%,
respectively, assuming baseline annual risk of PDAC of 200 cases per 100,000 person-years
after new-onset diabetes.[31]
For each of the models presented above, we also examined parsimonious models including
only risk factors associated with PDAC with OR> 2 (acute pancreatitis, chronic pancreatitis,
diabetes, abdominal pain, weight loss and jaundice). Parsimonious models performed slightly
lower than the QIC-driven models but by no more than 0.01 AUC point (S3 Table).
Considering that claims more distant from the index date potentially offer greater lead
time, we developed a prediction model based on claims 16–24 months prior to PDAC diagno-
sis, for which the AUC (0.552) was lower than that of the<15 months model. (S3 Table).
Discussion
In this analysis of older adults in the U.S., we showed that healthcare claims for risk factors
and PDAC-related symptoms and signs start to increase months ahead of PDAC diagnosis
and that healthcare utilization intensifies nearing the time of PDAC diagnosis. The AUC of the
prediction model built on 15 months of claims prior to the index date reached 0.68 when all
study subjects were considered and 0.73 among persons with new-onset diabetes. With omis-
sion of claims in the three months before diagnosis, the AUCs dropped substantially both for
Fig 1. Ratio of percentage of cases to controls with a healthcare claim for covariates of pancreatic cancer within 24-months prior to pancreatic cancer diagnosis,
by 3-month intervals.
https://doi.org/10.1371/journal.pone.0218580.g001
Healthcare claims and diagnosis of pancreatic cancer
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all cases and controls (0.58) and for persons with new-onset diabetics (0.63). At a specificity
threshold of 99%, models that incorporate all claims with 15 months of index date have limited
sensitivity of 16–18%, which drops to 4–5% by excluding the final 3 months of claims.
Two previously published models have focused on new-onset diabetes: one a model based
on new-onset U.K. diabetes patients aged�50 years that incorporated clinical diagnosis as
well as laboratory data from electronic health records, [12] another a model based on biochem-
ically-determined new-onset diabetes patients aged�50 years in Olmsted County, Minnesota,
that incorporated data on changes in glucose and weight. [13] The U.K. model reached an
AUC of 0.82 by internal validation and the Olmsted County model reached an AUC of 0.87 by
external validation within another population in Olmsted county (S4 Table). Our model in
new-onset diabetes patients, with AUC of 0.73, differs from previous models on three major
aspects: age range, regional scope, and type of data. Our study population comprised persons
aged� 68 years, who have higher baseline incidence of type 2 diabetes than younger persons,
therefore the likelihood that a recent diagnosis of diabetes could be attributable to pancreatic
cancer is lower. Our model comprised Medicare patients spanning 28 SEER regions in the
nation. Variability in documenting and billing clinical diagnoses may have been greater than
in the U.K. and in Olmsted County, with health systems that are less heterogeneous. [32, 33]
Finally, our model relied on insurance claims, rather than medical records, thus information
on laboratory test results and self-reported complaints were lacking. Because continuous for-
mats of laboratory test results (e.g., glucose level) and weight provide more granular
Table 2. Multivariable analysis of incidence of pancreatic cancer by covariates present at healthcare visits within 15 months prior to diagnosis of pancreatic cancer
or matched date in controls.
Variable Multivariable model Multivariable model excluding last 3 months of
claims
Odds Ratio
(95% CI)
P-value Odds Ratio
(95% CI)
P-value
Race �
Black 1.14 (1.08–1.20) < .001 1.22 (1.16–1.28) < .001
Other 0.88 (0.83–0.93) < .001 0.90 (0.95–0.94) < .001
Influenza vaccination in the last 12 months 0.82 (0.80–0.85) < .001 0.96 (0.94–0.99) 0.006
Presence of healthcare claims for clinical diagnoses
Acute pancreatitis 4.72 (4.20–5.30) < .001 3.11 (2.71–3.57) < .001
Chronic pancreatitis 3.72 (2.98–4.64) < .001 3.48 (2.74–4.41) < .001
Diabetes mellitus 1.52 (1.47–1.57) < .001 1.60 (1.55–1.65) < .001
Dyspepsia, gastritis, peptic ulcer disease 1.25 (1.16–1.34) < .001 1.08 (0.99–1.18) 0.067
Gallbladder disease 1.34 (1.02–1.76) 0.037 †
Depression 0.72 (0.68–0.76) < .001 0.80 (0.76–0.85) < .001
Presence of healthcare claims for symptoms and signs
Any abdominal pain 2.38 (2.30–2.47) < .001 1.26 (1.21–1.31) < .001
Chest pain 0.89 (0.86–0.92) < .001 †
Esophageal reflux 0.94 (0.90–0.99) 0.008 †
Weight loss 2.70 (2.57–2.84) < .001 1.57 (1.48–1.67) < .001
Jaundice 24.01 (20.63–27.95) < .001 3.77 (3.10–4.57) < .001
Nausea and/or vomiting † 0.90 (0.84–0.96) < .001
118584 observations were used in the multivariable models, which are adjusted for sex, age at diagnosis, and year of diagnosis, and takes into account correlated data
from the same subject.
� White race as a reference level.
† Dropped out of the multivariable model.
https://doi.org/10.1371/journal.pone.0218580.t002
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Table 3. Baseline patient characteristics stratified by incidence of pancreatic cancer in persons with new-onset DM. Data are presented as number of patients (%).
Variable Pancreatic cancer (N = 2319) Pancreatic cancer-Free (N = 3400) P-value
Sex
Male 1000 (43.12) 1517 (44.62) 0.263
Female 1319 (56.88) 1883 (55.38)
Age at diagnosis (Years)
68–70 341 (14.7) 466 (13.71) 0.001
71–75 583 (25.14) 801 (23.56)
76–80 622 (26.82) 818 (24.06)
81–85 456 (19.66) 745 (21.91)
86+ 317 (13.67) 570 (16.76)
Race
Black 249 (10.74) 315 (9.26) 0.031
Other 201 (8.67) 351 (10.32)
White 1869 (80.6) 2734 (80.41)
Influenza vaccination in the last 12 months
Yes 968 (41.74) 1434 (42.18) 0.744
No 1351 (58.26) 1966 (57.82)
Presence of healthcare claims for clinical diagnoses
Acute pancreatitis
� 15 months of index date 208 (8.97) 43 (1.26) < .001
Excluding final 3 months 85 (3.67) 33 (0.97) < .001
Chronic pancreatitis
� 15 months of index date 81 (3.49) 13 (0.38) < .001
Excluding final 3 months 36 (1.55) 11 (0.32) < .001
Poorly controlled diabetes mellitus
� 15 months of index date 807 (34.8) 859 (25.26) < .001
Excluding final 3 months 497 (21.43) 663 (19.5) 0.074
Dyspepsia, gastritis, peptic ulcer disease
� 15 months of index date 176 (7.59) 138 (4.06) < .001
Excluding final 3 months 86 (3.71) 109 (3.21) 0.304
Gallbladder disease
� 15 months of index date 25 (1.08) 14 (0.41) 0.003
Excluding final 3 months 12 (0.52) 11 (0.32) 0.255
Acute cholecystitis
� 15 months of index date 33 (1.42) 17 (0.5) < .001
Excluding final 3 months 16 (0.69) 14 (0.41) 0.153
Depression
� 15 months of index date 229 (9.87) 443 (13.03) < .001
Excluding final 3 months 169 (7.29) 365 (10.74) < .001
Presence of healthcare claims for symptoms and signs
Any abdominal pain
� 15 months of index date 1128 (48.64) 774 (22.76) < .001
Excluding final 3 months 541 (23.33) 657 (19.32) < .001
Chest pain
� 15 months of index date 824 (35.53) 1188 (34.94) 0.646
Excluding final 3 months 575 (24.8) 1014 (29.82) < .001
Gastrointestinal symptoms
� 15 months of index date 410 (17.68) 414 (12.18) < .001
(Continued)
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information on physiological state than binary diagnoses, incorporating such parameters may
explains more of the variation in PDAC risk.
Previously published pancreatic cancer prediction models on populations not selected by
diabetes status include a Korean nationwide study that incorporated laboratory data from reg-
ular health examinations (AUC = 0.81), [34] a population-based case-control study in Con-
necticut incorporating questionnaire-based data on ethnic ancestry, ABO blood group,
smoking cessation, pancreatitis and recent use of proton-pump inhibitor medications
(AUC = 0.764), [11] and a pancreatic cancer consortium (PanScan) analysis of multiple obser-
vational studies with questionnaire-based data on epidemiologic risk factors and blood group
genotype (AUC = 0.61). [35] (S4 Table) Our prediction model in the overall population
reached AUC of 0.68, which was lower compared to that estimated in the Korean and Con-
necticut models. We attribute lower performance to the lack of information on laboratory test
results and medications, to the lack of self-reported data not available in claims databases, as
well as to the older age of our population (�68 year). In addition to the advantage of laboratory
tests described above, over-the-counter medications like proton-pump inhibitors provide indi-
cations of abdominal pain prior to seeking help from health professional, thus adding more
granular and potentially earlier information on subclinical health changes. Also, Medicare
claims data do not include lifestyle risk factors of PDAC, such as smoking and alcohol con-
sumption, and family history of cancer, which increase the risk of PDAC. [36–38] The avail-
ability of such risk factor data would have improved our models. Considering that models
incorporating data on health changes leading up to pancreatic cancer diagnosis performed bet-
ter than the PanScan model that relied on data on static etiologic risk factors and ABO geno-
types [35] suggests that models based on such etiologic risk factors do not well identify exactly
when such factors should operate, compared to prediction models based on changes in health.
Table 3. (Continued)
Variable Pancreatic cancer (N = 2319) Pancreatic cancer-Free (N = 3400) P-value
Excluding final 3 months 223 (9.62) 344 (10.12) 0.533
Esophageal reflux
� 15 months of index date 522 (22.51) 618 (18.18) < .001
Excluding final 3 months 358 (15.44) 514 (15.12) 0.741
Jaundice
� 15 months of index date 283 (12.2) 18 (0.53) < .001
Excluding final 3 months 49 (2.11) 13 (0.38) < .001
Cachexia
� 15 months of index date 597 (25.74) 249 (7.32) < .001
Excluding final 3 months 219 (9.44) 188 (5.53) < .001
Nausea and/or vomiting
� 15 months of index date 325 (14.01) 339 (9.97) < .001
Excluding final 3 months 165 (7.12) 276 (8.12) 0.163
Fatigue
� 15 months of index date ^ ^
Excluding final 3 months ^ ^
Itching/pruritis
� 15 months of index date 75 (3.23) 73 (2.15) 0.011
Excluding final 3 months 33 (1.42) 56 (1.65) 0.502
^ Statistic not presented per SEER guidelines as cell counts were less than 11.
https://doi.org/10.1371/journal.pone.0218580.t003
Healthcare claims and diagnosis of pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0218580 June 25, 2019 11 / 16
Whether prediction models based on recent changes in health aid in detecting cancer suffi-
ciently early enough for better treatment options, especially potentially curative resection or
aggressive multifractionated radiation, is a critical question. Our sensitivity analysis results
excluding the final 3 months of claims before index date led to a substantial drop in AUC. One
of the strongest predictors was jaundice, which was associated with 24-fold risk of PDAC
including all claims within 15 months of index date and 3.8-fold risk excluding the final 3
months. The odds ratios for other strong predictors of pancreatic cancer, such as chronic pan-
creatitis, acute pancreatitis, abdominal pain and weight loss also attenuated substantially when
the final 3 months of claims were excluded. With longitudinal data from healthcare claims, we
observe that healthcare claims are comparatively more present in PDAC patients than controls
prior to PDAC diagnosis; however, often these health changes are noted very close (<3
months) to the diagnosis of PDAC, thus limiting their predictive value for early detection.
In our analyses, one limitation of using Medicare files is that healthcare claims not billed to
Medicare would not have been reflected in the files. By restricting the population to those con-
tinuously enrolled in both Medicare Parts A (inpatient care) and B (outpatient care), we lim-
ited the population to those who have opted for fee-for-service outpatient reimbursement
through Medicare, which therefore would have records of most services covered for its mem-
bers. Another limitation of Medicare claims data is that claims do not distinguish incident
from prevalent conditions. Indeed, knowing the duration of a condition since onset can help
improve the model as demonstrated by Risch et al. [11] For conditions like diabetes, pancreati-
tis and dyspepsia, the strength of the association with PDAC decreases with time since onset;
thus, parameterizing the timing of the onset of disease would enhance the fit of the model.
Table 4. Multivariable analysis of incidence of pancreatic cancer among persons with new-onset diabetes by covariates present at healthcare visits within 15 months
prior to diagnosis of pancreatic cancer or matched date in controls.
Variable Multivariable model Multivariable model excluding last 3 months of
claims
Odds Ratio
(95% CI)
P-value Odds Ratio
(95% CI)
P-value
Race �
Black 0.99 (0.81–1.20) 0.889 1.12 (0.93–1.35) 0.217
Other 0.75 (0.61–0.92) 0.005 0.78 (0.65–0.95) 0.012
Influenza vaccination in the last 12 months 0.92 (0.81–1.03) 0.158 1.01 (0.91–1.14) 0.800
Presence of healthcare claims for clinical diagnoses
Acute pancreatitis 3.89 (2.67–5.68) < .001 2.89 (1.82–4.58) < .001
Chronic pancreatitis 2.42 (1.23–4.76) 0.010 1.92 (0.91–4.04) 0.087
Poorly controlled diabetes mellitus 1.63 (1.43–1.85) < .001 †
Depression 0.49 (0.39–0.61) < .001 0.64 (0.52–0.79) < .001
Presence of healthcare claims for symptoms and signs
Any abdominal pain 2.52 (2.21–2.88) < .001 1.25 (1.08–1.44) 0.002
Chest pain † 0.76 (0.66–0.86) < .001
Weight loss / Anorexia Cachexia 3.64 (3.06–4.33) < .001 1.82 (1.47–2.25) < .001
Jaundice 17.95 (10.93–29.48) < .001 3.68 (1.94–7.00) < .001
Nausea and/or vomiting 0.74 (0.60–0.91) 0.005 †
5719 observations were used in the multivariable models, which are adjusted for sex, age at diagnosis, and year of diagnosis, and takes into account correlated data from
the same subject.
� White race as a reference level.
† Dropped out of the multivariable model.
https://doi.org/10.1371/journal.pone.0218580.t004
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Another limitation of Medicare claims data is the lack of representation of younger people
who may still be at risk of PDAC. Regardless, the mean age of PDAC diagnosis is 70, [17] thus
our model applies to a majority of older persons in U.S at risk for PDAC. Although we aimed
to include a comprehensive list of risk factors and symptoms of PDAC, some factors may not
have been represented in our analysis. An example is back pain, which has been associated
PDAC with odds ratios ranging from 1.3 to 1.4. [39, 40] While including additional factors
could improve the prediction model, relatively weak associations are unlikely to improve the
predictive performance of the model appreciably.
Conclusion
We created a PDAC prediction model that applies to Medicare enrollees living in SEER
regions in the U.S. The model provides some information bearing upon the emergent diagno-
sis of pancreatic cancer, but not enough on its own to be useful in population screening.
Excluding the final 3 months of claims prior to PDAC diagnosis reduced the discriminative
performance of the model appreciably. Future models should consider sensitivity analyses
excluding health changes noted in the final months of PDAC diagnosis in order to evaluate
true clinical utility of prediction models for PDAC early detection.
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Table 5. Performance characteristics for prediction models of pancreatic cancer based on healthcare claims.
Population Time period for claims included in the
multivariable model
AUC (95% CI) Optimism-corrected AUC
(95% CI)
Specificity Sensitivity
All cases and controls (cases 29,646;
controls 88,938)
A.�15 months period prior to index date 0.683 (0.680–
0.687)
0.682 (0.678–0.686) � 99% < 16.17%
95–98.9% 16.17–
27.84%
< 95% > 27.84%
All cases and controls (cases 29,646;
controls 88,938)
Model A excluding last 3 months of claims
prior to index date
0.578 (0.575–
0.582)
0.577 (0.573–0.581) � 99% < 4.71%
95–98.9% 4.71–11.79%
< 95% > 11.79%
Cases and controls (cases 23,332;
controls 88,938)
Model A excluding non-microscopically
confirmed cases
0.703 (0.699–
0.707)
0.702 (0.698–0.706) � 99% < 18.14%
95–98.9% 18.14–
30.05%
< 95% > 30.05%
Cases and controls with new-onset
diabetes
(cases 2,319; controls 3,400)
B.�15 months period prior to index date 0.735 (0.721–
0.748)
0.730 (0.717–0.744) � 99% < 18.24%
95–98.9% 18.24–
33.89%
< 95% > 33.89%
Cases and controls with new-onset
diabetes
(cases 2,319; controls 3,400)
Model B excluding last 3 months of claims prior
to index date
0.635 (0.621–
0.650)
0.626 (0.612–0.641) � 99% < 4.44%
95–98.9% 4.44–13.76%
< 95% > 13.76%
Cases and controls with new-onset
diabetes
(cases 1,873; controls 3,400)
Model B excluding non-microscopically
confirmed cases
0.754 (0.739–
0.768)
0.747 (0.733–0.761) � 99% < 20.12%
95–98.9% 20.12–
36.15%
< 95% > 36.15%
https://doi.org/10.1371/journal.pone.0218580.t005
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